Atlas Trials

Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type

4 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type

RecordFirmDate
Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy (NCT06834373)Mayo Clinic2025-04-02
Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma (NCT05821088)David Bond, MD2023-06-29
TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma (NCT05507541)Mayo Clinic2023-04-19
Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas (NCT03038672)National Cancer Institute (NCI)2018-12-21

Track Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type automatically

Every clearance here is in the API, with alerts when new ones post.